Grid reliability and resiliency remain challenged because distributed energy resources (DER) and microgrids have yet to drive transformative change in electric power systems.
Nhu Energy addresses this gap with high-performing digital operating technology (OT) that enables clean, flexible, and resilient distributed power at scale.
Our interoperable Operating Technology as a Service (OTaaS®) solutions deliver proven value to mission-critical facilities, including:
Myosin Therapeutics is a clinical and R&D-stage biotech C-corp incorporated in Delaware and based in South Florida.
The company’s innovative science was developed collaboratively in the labs of Drs. Miller, Griffin, and Kamenecka at the Department of Molecular Medicine, Wertheim UF Scripps Institute for Biomedical Innovation & Technology—a University of Florida research institute dedicated to new treatments.
PHIOGEN is a biotechnology company developing next-generation bacteriophage therapeutics to combat the global crisis of antimicrobial resistance (AMR).
Drug-resistant infections are among the leading causes of death worldwide, with limited treatment options and high recurrence rates. Current antibiotics often fail to prevent reinfection, leaving millions vulnerable to chronic disease.
SkyNano is a science-driven company pioneering a sustainable pathway to produce low-cost advanced carbon-based materials directly from carbon dioxide.
Using a proprietary electrochemical process developed at Vanderbilt University, SkyNano captures CO2 from industrial emissions and converts it into valuable solid carbon nanomaterials—without fossil feedstocks.
Nutrivert, based in Atlanta, is a preclinical-stage biotechnology company with worldwide exclusive patent rights to a breakthrough inflammation-sparing NOD2 agonist platform.
For 75 years, broad-spectrum antibiotics have transformed bacterial infections. Viral diseases deserve the same breakthrough: a simple prophylactic that prevents symptoms from common colds to pandemic threats like flu or coronavirus.
Tricuspid regurgitation (TR) is the most common valvular heart disease, affecting more than 20 million people in the US, including 1.8 million with severe dysfunction.
TR occurs when the tricuspid valve fails to close properly, allowing blood to flow backward from the right ventricle to the right atrium. As severity increases, the heart works harder, leading to reduced quality of life, end-organ dysfunction, and higher mortality.
Falcomm is a fabless semiconductor company based in Atlanta, Georgia, specializing in ultra-efficient integrated power amplifiers (PAs) and front-end modules that significantly reduce power consumption and size in wireless and satellite systems.
30 million Americans suffer from food allergies, with 6 million affected by peanut allergy—a life-threatening condition with no robust, disease-modifying treatments widely adopted.
Current management relies on strict avoidance and emergency epinephrine, leaving patients and families in constant fear of accidental exposure.
